<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phgenomics</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакогенетика и фармакогеномика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacogenetics and Pharmacogenomics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0527</issn><issn pub-type="epub">2686-8849</issn><publisher><publisher-name>LLC "Izdatelstvo OKI"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2588-0527-2024-2-29-36</article-id><article-id custom-type="edn" pub-id-type="custom">RZAZIM</article-id><article-id custom-type="elpub" pub-id-type="custom">phgenomics-290</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CURRENT REVIEW</subject></subj-group></article-categories><title-group><article-title>Революция в здравоохранении: роль систем CRISPR-Cas в прецизионной медицине</article-title><trans-title-group xml:lang="en"><trans-title>Revolutionizing healthcare: the role of CRISPR-Cas systems in precision medicine</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0085-3284</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Киролос</surname><given-names>Эскандар</given-names></name><name name-style="western" xml:lang="en"><surname>Kirolos</surname><given-names>Eskandar</given-names></name></name-alternatives><bio xml:lang="ru"><p>Киролос Эскандар — факультет медицины и хирургии</p><p>Каир</p></bio><bio xml:lang="en"><p>Kirolos Eskandar — Faculty of Medicine and Surgery </p><p>Cairo </p></bio><email xlink:type="simple">kiroloss.eskandar@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Хелуанский университет<country>Египет</country></aff><aff xml:lang="en">Helwan University<country>Egypt</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>31</day><month>12</month><year>2024</year></pub-date><volume>0</volume><issue>2</issue><fpage>29</fpage><lpage>36</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Киролос Э., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Киролос Э.</copyright-holder><copyright-holder xml:lang="en">Kirolos E.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/290">https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/290</self-uri><abstract><sec><title>Введение</title><p>Введение. Технология CRISPR (Кластерные короткие палиндромные повторы с регулярными интервалами) была признана революционным достижением в области биомедицины, обеспечивающим непревзойдённую точность и универсальность редактирования генома. В этом обзоре рассматривается преобразующий потенциал CRISPR как диагностического и терапевтического инструмента для лечения различных заболеваний.</p></sec><sec><title>Методы</title><p>Методы. Систематический обзор литературы был проведён в соответствии с руководящими принципами PRISMA (Предпочтительные элементы отчётности для систематических обзоров и метаанализа). Для выявления соответствующих исследований, опубликованных в период с января 2015 по январь 2025 года, был проведён всесторонний поиск в PubMed, Scopus, Google Scholar и Web of Science. Критерии включения были ориентированы на рецензируемые статьи, в которых обсуждались диагностика на основе CRISPR, терапевтические применения и технологические достижения. Исследования были отобраны, оценены на предмет качества с использованием системы CASP и распределены по тематическим областям для анализа.</p></sec><sec><title>Результаты</title><p>Результаты. Диагностические платформы на основе CRISPR, такие как SHERLOCK и DETECTR, были проанализированы на предмет их чувствительности и скорости обнаружения патогенов, биомаркеров рака и генетических мутаций. Новые инновации, в том числе редактирование с использованием праймеров и оснований, были изучены на предмет их роли в расширении возможностей технологии CRISPR. Кроме того, были обсуждены усовершенствования в механизмах доставки и использование альтернативных белков Cas с точки зрения их влияния на клиническую применимость.</p></sec><sec><title>Выводы</title><p>Выводы. Рассмотрены этические, нормативные проблемы, доступность технологии CRISPR, что подчёркивает важность ответственной разработки и справедливого внедрения. Связывая передовые достижения с проблемами трансляции, этот обзор подчёркивает важную роль CRISPR в формировании будущего прецизионной медицины и глобального здравоохранения.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has been recognized as a revolutionary advancement in the biomedical field, offering unparalleled precision and versatility in genome editing. This review examines the transformative potential of CRISPR as a diagnostic and therapeutic tool for various diseases.</p></sec><sec><title>Methods</title><p>Methods. A systematic review was conducted following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. A comprehensive search of PubMed, Scopus, Google Scholar, and Web of Science was performed to identify relevant Studies published between January 2015 and January 2025. The inclusion criteria focused on peer-reviewed articles discussing CRISPR-based diagnostics, therapeutic applications, and technological advancements. Studies were screened, assessed for quality using the CASP framework, and categorized into thematic areas for analysis.</p></sec><sec><title>Results</title><p>Results. CRISPR-based diagnostic platforms, such as SHERLOCK and DETECTR, were analyzed for their sensitivity and rapidity in detecting pathogens, cancer biomarkers, and genetic mutations. Emerging innovations, including prime and base editing, have been explored for their role in expanding the capabilities of CRISPR. Additionally, advancements in delivery mechanisms and the use of alternative Cas proteins have been discussed for their impact on clinical applicability.</p></sec><sec><title>Conclusions</title><p>Conclusions. Ethical, regulatory, and accessibility challenges associated with CRISPR technology are highlighted, emphasizing the importance of responsible development and equitable deployment. This review connects cutting-edge advancements with translational challenges and underscores the significant role of CRISPR in shaping the future of precision medicine and global health.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>диагностика на основе CRISPR</kwd><kwd>редактирование генов</kwd><kwd>прецизионная медицина</kwd><kwd>технологии CRISPR-Cas</kwd><kwd>биомедицинские инновации</kwd></kwd-group><kwd-group xml:lang="en"><kwd>CRISPR-based diagnostics</kwd><kwd>gene editing</kwd><kwd>precision medicine</kwd><kwd>CRISPR-Cas technologies</kwd><kwd>biomedical innovation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Pastori D, Cormaci VM, Marucci S, et al. A Comprehensive Review of 1. Li T, Li S, Kang Y, Zhou J, Yi M. Harnessing the evolving CRISPR/ Cas9 for precision oncology. Journal of Translational Medicine. 2024;22(1). https://doi.org/10.1186/s12967-024-05570-4</mixed-citation><mixed-citation xml:lang="en">Pastori D, Cormaci VM, Marucci S, et al. A Comprehensive Review of 1. Li T, Li S, Kang Y, Zhou J, Yi M. Harnessing the evolving CRISPR/ Cas9 for precision oncology. Journal of Translational Medicine. 2024;22(1). https://doi.org/10.1186/s12967-024-05570-4</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Aljabali AA, El-Tanani M, Tambuwala MM. Principles of CRISPRCas9 technology: Advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 2024;92:105338. https://doi.org/10.1016/j.jddst.2024.105338</mixed-citation><mixed-citation xml:lang="en">Aljabali AA, El-Tanani M, Tambuwala MM. Principles of CRISPRCas9 technology: Advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 2024;92:105338. https://doi.org/10.1016/j.jddst.2024.105338</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wani AK, Akhtar N, Mir TUG, Chopra C, Singh R, Hong JC, Kadam US. CRISPR/Cas12a-based biosensors for environmental monitoring and diagnostics. Environmental Technology &amp; Innovation. 2024;34:103625. https://doi.org/10.1016/j.eti.2024.103625</mixed-citation><mixed-citation xml:lang="en">Wani AK, Akhtar N, Mir TUG, Chopra C, Singh R, Hong JC, Kadam US. CRISPR/Cas12a-based biosensors for environmental monitoring and diagnostics. Environmental Technology &amp; Innovation. 2024;34:103625. https://doi.org/10.1016/j.eti.2024.103625</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Puig-Serra P, Casado-Rosas MC, Martinez-Lage M, Olalla-Sastre B, Alonso-Yanez A, Torres-Ruiz R, Rodriguez-Perales S. CRISPR Approaches for the Diagnosis of Human Diseases. Int J Mol Sci. 2022 Feb 3;23(3):1757. doi: 10.3390/ijms23031757.</mixed-citation><mixed-citation xml:lang="en">Puig-Serra P, Casado-Rosas MC, Martinez-Lage M, Olalla-Sastre B, Alonso-Yanez A, Torres-Ruiz R, Rodriguez-Perales S. CRISPR Approaches for the Diagnosis of Human Diseases. Int J Mol Sci. 2022 Feb 3;23(3):1757. doi: 10.3390/ijms23031757.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Baig MMFA, Chair SY, Chien WT. CRISPR/Cas systems for genomic Editing, biochemical Sensing, Bioanalysis, and diagnostics. Microchemical Journal. 2025;112638. https://doi.org/10.1016/j.microc.2024.112638</mixed-citation><mixed-citation xml:lang="en">Baig MMFA, Chair SY, Chien WT. CRISPR/Cas systems for genomic Editing, biochemical Sensing, Bioanalysis, and diagnostics. Microchemical Journal. 2025;112638. https://doi.org/10.1016/j.microc.2024.112638</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ghouneimy A, Mahas A, Marsic T, Aman R, Mahfouz M. CRISPRBased Diagnostics: Challenges and Potential Solutions toward Point-of-Care Applications. ACS Synth Biol. 2023 Jan 20;12(1):1-16. doi: 10.1021/acssynbio.2c00496.</mixed-citation><mixed-citation xml:lang="en">Ghouneimy A, Mahas A, Marsic T, Aman R, Mahfouz M. CRISPRBased Diagnostics: Challenges and Potential Solutions toward Point-of-Care Applications. ACS Synth Biol. 2023 Jan 20;12(1):1-16. doi: 10.1021/acssynbio.2c00496.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kaminski MM, Abudayyeh OO, Gootenberg JS, Zhang F, Collins JJ. CRISPR-based diagnostics. Nat Biomed Eng. 2021 Jul;5(7):643-656. doi: 10.1038/s41551-021-00760-7.</mixed-citation><mixed-citation xml:lang="en">Kaminski MM, Abudayyeh OO, Gootenberg JS, Zhang F, Collins JJ. CRISPR-based diagnostics. Nat Biomed Eng. 2021 Jul;5(7):643-656. doi: 10.1038/s41551-021-00760-7.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ebrahimi S, Khanbabaei H, Abbasi S, Fani M, Soltani S, Zandi M, Najafimemar Z. CRISPR-Cas System: A Promising Diagnostic Tool for Covid-19. Avicenna J Med Biotechnol. 2022 Jan-Mar;14(1):3-9. doi: 10.18502/ajmb.v14i1.8165.</mixed-citation><mixed-citation xml:lang="en">Ebrahimi S, Khanbabaei H, Abbasi S, Fani M, Soltani S, Zandi M, Najafimemar Z. CRISPR-Cas System: A Promising Diagnostic Tool for Covid-19. Avicenna J Med Biotechnol. 2022 Jan-Mar;14(1):3-9. doi: 10.18502/ajmb.v14i1.8165.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J, Liu F, Long J, Jin Y, Chen S, Duan G, Yang H. The application of CRISPR-Cas system in Staphylococcus aureus infection. Heliyon. 2024$10(14):e34383. https://doi.org/10.1016/j.heliyon.2024.e34383</mixed-citation><mixed-citation xml:lang="en">Wang J, Liu F, Long J, Jin Y, Chen S, Duan G, Yang H. The application of CRISPR-Cas system in Staphylococcus aureus infection. Heliyon. 2024$10(14):e34383. https://doi.org/10.1016/j.heliyon.2024.e34383</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Deol P, Madhwal A, Sharma G, Kaushik R, Malik YS. CRISPR use in diagnosis and therapy for COVID-19. Methods Microbiol. 2022;50:123-150. doi: 10.1016/bs.mim.2022.03.002.</mixed-citation><mixed-citation xml:lang="en">Deol P, Madhwal A, Sharma G, Kaushik R, Malik YS. CRISPR use in diagnosis and therapy for COVID-19. Methods Microbiol. 2022;50:123-150. doi: 10.1016/bs.mim.2022.03.002.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hadi R, Poddar A, Sonnaila S, Bhavaraju VSM, Agrawal S. Advancing CRISPR-Based Solutions for COVID-19 Diagnosis and Therapeutics. Cells. 2024 Oct 30;13(21):1794. doi: 10.3390/cells13211794.</mixed-citation><mixed-citation xml:lang="en">Hadi R, Poddar A, Sonnaila S, Bhavaraju VSM, Agrawal S. Advancing CRISPR-Based Solutions for COVID-19 Diagnosis and Therapeutics. Cells. 2024 Oct 30;13(21):1794. doi: 10.3390/cells13211794.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, Rashidi M, Arshi A, MokhtariFarsani A. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024 Jan 9;23(1):9. doi: 10.1186/s12943-023-01925-5. Erratum in: Mol Cancer. 2024 Feb 27;23(1):43. doi: 10.1186/s12943-024-01961-9.</mixed-citation><mixed-citation xml:lang="en">Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, Rashidi M, Arshi A, MokhtariFarsani A. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024 Jan 9;23(1):9. doi: 10.1186/s12943-023-01925-5. Erratum in: Mol Cancer. 2024 Feb 27;23(1):43. doi: 10.1186/s12943-024-01961-9.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X, Wang L, Lin H, Zhu Y, Huang D, Lai M, Xi X, Huang J, Zhang W, Zhong T. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy. Front Oncol. 2024 Jan 25;14:1303335. doi: 10.3389/fonc.2024.1303335.</mixed-citation><mixed-citation xml:lang="en">Wang X, Wang L, Lin H, Zhu Y, Huang D, Lai M, Xi X, Huang J, Zhang W, Zhong T. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy. Front Oncol. 2024 Jan 25;14:1303335. doi: 10.3389/fonc.2024.1303335.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hassan YM, Mohamed AS, Hassan YM, El-Sayed WM. Recent developments and future directions in point-of-care next-generation CRISPRbased rapid diagnosis. Clinical and experimental medicine. 2025;25(1):33. https://doi.org/10.1007/s10238-024-01540-8.</mixed-citation><mixed-citation xml:lang="en">Hassan YM, Mohamed AS, Hassan YM, El-Sayed WM. Recent developments and future directions in point-of-care next-generation CRISPRbased rapid diagnosis. Clinical and experimental medicine. 2025;25(1):33. https://doi.org/10.1007/s10238-024-01540-8.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Carpenter Rob E. Navigating the new norm: The FDA's final rule on laboratory developed tests (LDTs) and its impact on clinical laboratory operations. Clinical Microbiology Newsletter. 2024;48:Pages 1-8. https://doi.org/10.1016/j.clinmicnews.2024.09.001.</mixed-citation><mixed-citation xml:lang="en">Carpenter Rob E. Navigating the new norm: The FDA's final rule on laboratory developed tests (LDTs) and its impact on clinical laboratory operations. Clinical Microbiology Newsletter. 2024;48:Pages 1-8. https://doi.org/10.1016/j.clinmicnews.2024.09.001.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Abdelnour SA, Xie L, Hassanin AA, Zuo E, Lu Y. The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases. Front Cell Dev Biol. 2021 Dec 15;9:699597. doi: 10.3389/fcell.2021.699597.</mixed-citation><mixed-citation xml:lang="en">Abdelnour SA, Xie L, Hassanin AA, Zuo E, Lu Y. The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases. Front Cell Dev Biol. 2021 Dec 15;9:699597. doi: 10.3389/fcell.2021.699597.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lattanzi A, Camarena J, Lahiri P, Segal H, Srifa W, Vakulskas CA, Frock RL, Kenrick J, Lee C, Talbott N, Skowronski J, Cromer MK, Charlesworth CT, Bak RO, Mantri S, Bao G, DiGiusto D, Tisdale J, Wright JF, Bhatia N, Roncarolo MG, Dever DP, Porteus MH. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med. 2021 Jun 16;13(598):eabf2444. doi: 10.1126/scitranslmed.abf2444.</mixed-citation><mixed-citation xml:lang="en">Lattanzi A, Camarena J, Lahiri P, Segal H, Srifa W, Vakulskas CA, Frock RL, Kenrick J, Lee C, Talbott N, Skowronski J, Cromer MK, Charlesworth CT, Bak RO, Mantri S, Bao G, DiGiusto D, Tisdale J, Wright JF, Bhatia N, Roncarolo MG, Dever DP, Porteus MH. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med. 2021 Jun 16;13(598):eabf2444. doi: 10.1126/scitranslmed.abf2444.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tariq H, Khurshid F, Khan MH, Dilshad A, Zain A, Rasool W, Jawaid A, Kunwar D, Khanduja S, Akbar A. CRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review. Ann Med Surg (Lond). 2024 Aug 14;86(10):5938-5946. doi: 10.1097/MS9.0000000000002478.</mixed-citation><mixed-citation xml:lang="en">Tariq H, Khurshid F, Khan MH, Dilshad A, Zain A, Rasool W, Jawaid A, Kunwar D, Khanduja S, Akbar A. CRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review. Ann Med Surg (Lond). 2024 Aug 14;86(10):5938-5946. doi: 10.1097/MS9.0000000000002478.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tao R, Han X, Bai X, Yu J, Ma Y, Chen W, Zhang D, Li Z. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology. Front Immunol. 2024 Feb 21;15:1354825. doi: 10.3389/fimmu.2024.1354825.</mixed-citation><mixed-citation xml:lang="en">Tao R, Han X, Bai X, Yu J, Ma Y, Chen W, Zhang D, Li Z. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology. Front Immunol. 2024 Feb 21;15:1354825. doi: 10.3389/fimmu.2024.1354825.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lei T, Wang Y, Zhang Y, Yang Y, Cao J, Huang J, Chen J, Chen H, Zhang J, Wang L, Xu X, Gale RP, Wang L. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024 Dec;38(12):2517-2543. doi: 10.1038/s41375-024-02444-y.</mixed-citation><mixed-citation xml:lang="en">Lei T, Wang Y, Zhang Y, Yang Y, Cao J, Huang J, Chen J, Chen H, Zhang J, Wang L, Xu X, Gale RP, Wang L. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024 Dec;38(12):2517-2543. doi: 10.1038/s41375-024-02444-y.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zahedipour F, Zahedipour F, Zamani P, Jaafari MR, Sahebkar A. Harnessing CRISPR technology for viral therapeutics and vaccines: from preclinical studies to clinical applications. Virus Res. 2024 Mar;341:199314. doi: 10.1016/j.virusres.2024.199314.</mixed-citation><mixed-citation xml:lang="en">Zahedipour F, Zahedipour F, Zamani P, Jaafari MR, Sahebkar A. Harnessing CRISPR technology for viral therapeutics and vaccines: from preclinical studies to clinical applications. Virus Res. 2024 Mar;341:199314. doi: 10.1016/j.virusres.2024.199314.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Stone D, Long KR, Loprieno MA, De Silva Feelixge HS, Kenkel EJ, Liley RM, Rapp S, Roychoudhury P, Nguyen T, Stensland L, Colón-Thillet R, Klouser LM, Weber ND, Le C, Wagoner J, Goecker EA, Li AZ, Eichholz K, Corey L, Tyrrell DL, Greninger AL, Huang ML, Polyak SJ, Aubert M, Sagartz JE, Jerome KR. CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. Mol Ther Methods Clin Dev. 2020 Nov 26;20:258-275. doi: 10.1016/j.omtm.2020.11.014.</mixed-citation><mixed-citation xml:lang="en">Stone D, Long KR, Loprieno MA, De Silva Feelixge HS, Kenkel EJ, Liley RM, Rapp S, Roychoudhury P, Nguyen T, Stensland L, Colón-Thillet R, Klouser LM, Weber ND, Le C, Wagoner J, Goecker EA, Li AZ, Eichholz K, Corey L, Tyrrell DL, Greninger AL, Huang ML, Polyak SJ, Aubert M, Sagartz JE, Jerome KR. CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. Mol Ther Methods Clin Dev. 2020 Nov 26;20:258-275. doi: 10.1016/j.omtm.2020.11.014.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Nouri Nojadeh J, Bildiren Eryilmaz NS, Ergüder BI. CRISPR/Cas9 genome editing for neurodegenerative diseases. EXCLI J. 2023 Jul 3;22:567-582. doi: 10.17179/excli2023-6155.</mixed-citation><mixed-citation xml:lang="en">Nouri Nojadeh J, Bildiren Eryilmaz NS, Ergüder BI. CRISPR/Cas9 genome editing for neurodegenerative diseases. EXCLI J. 2023 Jul 3;22:567-582. doi: 10.17179/excli2023-6155.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kolanu ND. CRISPR-Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications. Glob Med Genet. 2024 Mar 29;11(1):113-122. doi: 10.1055/s-0044-1785234.</mixed-citation><mixed-citation xml:lang="en">Kolanu ND. CRISPR-Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications. Glob Med Genet. 2024 Mar 29;11(1):113-122. doi: 10.1055/s-0044-1785234.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zeballos C MA, Gaj T. Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy. Trends Biotechnol. 2021 Jul;39(7):692-705. doi: 10.1016/j.tibtech.2020.10.010.</mixed-citation><mixed-citation xml:lang="en">Zeballos C MA, Gaj T. Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy. Trends Biotechnol. 2021 Jul;39(7):692-705. doi: 10.1016/j.tibtech.2020.10.010.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet. 2018 Dec;19(12):770-788. doi: 10.1038/s41576-018-0059-1. Erratum in: Nat Rev Genet. 2018 Dec;19(12):801. doi: 10.1038/s41576-018-0068-0.</mixed-citation><mixed-citation xml:lang="en">Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet. 2018 Dec;19(12):770-788. doi: 10.1038/s41576-018-0059-1. Erratum in: Nat Rev Genet. 2018 Dec;19(12):801. doi: 10.1038/s41576-018-0068-0.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Chen PJ, Liu DR. Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet. 2023 Mar;24(3):161-177. doi: 10.1038/s41576-022-00541-1.</mixed-citation><mixed-citation xml:lang="en">Chen PJ, Liu DR. Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet. 2023 Mar;24(3):161-177. doi: 10.1038/s41576-022-00541-1.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Paul B, Montoya G. CRISPR-Cas12a: Functional overview and applications. Biomed J. 2020 Feb;43(1):8-17. doi: 10.1016/j.bj.2019.10.005.</mixed-citation><mixed-citation xml:lang="en">Paul B, Montoya G. CRISPR-Cas12a: Functional overview and applications. Biomed J. 2020 Feb;43(1):8-17. doi: 10.1016/j.bj.2019.10.005.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta R, Ghosh A, Chakravarti R, Singh R, Ravichandiran V, Swarnakar S, Ghosh D. Cas13d: A New Molecular Scissor for Transcriptome Engineering. Frontiers in cell and developmental biology. 2022;10:866800. https://doi.org/10.3389/fcell.2022.866800.</mixed-citation><mixed-citation xml:lang="en">Gupta R, Ghosh A, Chakravarti R, Singh R, Ravichandiran V, Swarnakar S, Ghosh D. Cas13d: A New Molecular Scissor for Transcriptome Engineering. Frontiers in cell and developmental biology. 2022;10:866800. https://doi.org/10.3389/fcell.2022.866800.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Asmamaw Mengstie M. Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges. Front Bioeng Biotechnol. 2022 May 12;10:895713. doi: 10.3389/fbioe.2022.895713.</mixed-citation><mixed-citation xml:lang="en">Asmamaw Mengstie M. Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges. Front Bioeng Biotechnol. 2022 May 12;10:895713. doi: 10.3389/fbioe.2022.895713.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Wei PS, Thota N, John G, Chang E, Lee S, Wang Y, Ma Z, Tsai YH, Mei KC. Enhancing RNA-lipid nanoparticle delivery: Organ- and cellspecificity and barcoding strategies. J Control Release. 2024 Nov;375:366-388. doi: 10.1016/j.jconrel.2024.08.030.</mixed-citation><mixed-citation xml:lang="en">Wei PS, Thota N, John G, Chang E, Lee S, Wang Y, Ma Z, Tsai YH, Mei KC. Enhancing RNA-lipid nanoparticle delivery: Organ- and cellspecificity and barcoding strategies. J Control Release. 2024 Nov;375:366-388. doi: 10.1016/j.jconrel.2024.08.030.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Ayanoğlu FB, Elçin AE, Elçin YM. Bioethical issues in genome editing by CRISPR-Cas9 technology. Turk J Biol. 2020 Apr 2;44(2):110-120. doi: 10.3906/biy-1912-52.</mixed-citation><mixed-citation xml:lang="en">Ayanoğlu FB, Elçin AE, Elçin YM. Bioethical issues in genome editing by CRISPR-Cas9 technology. Turk J Biol. 2020 Apr 2;44(2):110-120. doi: 10.3906/biy-1912-52.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Lau PL. Evolved Eugenics and Reinforcement of "Othering": Renewed Ethico-Legal Perspectives of Genome Editing in Reproduction. BioTech (Basel). 2023 Jul 11;12(3):51. doi: 10.3390/biotech12030051.</mixed-citation><mixed-citation xml:lang="en">Lau PL. Evolved Eugenics and Reinforcement of "Othering": Renewed Ethico-Legal Perspectives of Genome Editing in Reproduction. BioTech (Basel). 2023 Jul 11;12(3):51. doi: 10.3390/biotech12030051.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">National Human Genome Research Institute. (n.d.). Ethical concerns about genome editing. Retrieved January 25, 2025, from https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns</mixed-citation><mixed-citation xml:lang="en">National Human Genome Research Institute. (n.d.). Ethical concerns about genome editing. Retrieved January 25, 2025, from https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Genetic Literacy Project. (n.d.). EU germline and embryonic gene editing regulations. Retrieved January 25, 2025, from https://crispr-geneediting-regs-tracker.geneticliteracyproject.org/eu-germline-embryonic/</mixed-citation><mixed-citation xml:lang="en">Genetic Literacy Project. (n.d.). EU germline and embryonic gene editing regulations. Retrieved January 25, 2025, from https://crispr-geneediting-regs-tracker.geneticliteracyproject.org/eu-germline-embryonic/</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Rueda J, de Miguel Beriain Í, Montoliu L. Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative. CRISPR J. 2024 Oct;7(5):220-226. doi: 10.1089/crispr.2024.0042.</mixed-citation><mixed-citation xml:lang="en">Rueda J, de Miguel Beriain Í, Montoliu L. Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative. CRISPR J. 2024 Oct;7(5):220-226. doi: 10.1089/crispr.2024.0042.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Subica AM. CRISPR in Public Health: The Health Equity Implications and Role of Community in Gene-Editing Research and Applications. Am J Public Health. 2023 Aug;113(8):874-882. doi: 10.2105/AJPH.2023.307315.</mixed-citation><mixed-citation xml:lang="en">Subica AM. CRISPR in Public Health: The Health Equity Implications and Role of Community in Gene-Editing Research and Applications. Am J Public Health. 2023 Aug;113(8):874-882. doi: 10.2105/AJPH.2023.307315.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Liu W, Li L, Jiang J, Wu M, Lin P. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precis Clin Med. 2021 Jul 10;4(3):179-191. doi: 10.1093/pcmedi/pbab014.</mixed-citation><mixed-citation xml:lang="en">Liu W, Li L, Jiang J, Wu M, Lin P. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precis Clin Med. 2021 Jul 10;4(3):179-191. doi: 10.1093/pcmedi/pbab014.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L, He W, Fu R, Wang S, Chen Y, Xu H. Guide-specific loss of efficiency and off-target reduction with Cas9 variants. Nucleic Acids Res. 2023 Oct 13;51(18):9880-9893. doi: 10.1093/nar/gkad702.</mixed-citation><mixed-citation xml:lang="en">Zhang L, He W, Fu R, Wang S, Chen Y, Xu H. Guide-specific loss of efficiency and off-target reduction with Cas9 variants. Nucleic Acids Res. 2023 Oct 13;51(18):9880-9893. doi: 10.1093/nar/gkad702.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Mehta A, Merkel OM. Immunogenicity of Cas9 Protein. J Pharm Sci. 2020 Jan;109(1):62-67. doi: 10.1016/j.xphs.2019.10.003.</mixed-citation><mixed-citation xml:lang="en">Mehta A, Merkel OM. Immunogenicity of Cas9 Protein. J Pharm Sci. 2020 Jan;109(1):62-67. doi: 10.1016/j.xphs.2019.10.003.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Ewaisha R, Anderson KS. Immunogenicity of CRISPR therapeuticsCritical considerations for clinical translation. Front Bioeng Biotechnol. 2023 Feb 16;11:1138596. doi: 10.3389/fbioe.2023.1138596.</mixed-citation><mixed-citation xml:lang="en">Ewaisha R, Anderson KS. Immunogenicity of CRISPR therapeuticsCritical considerations for clinical translation. Front Bioeng Biotechnol. 2023 Feb 16;11:1138596. doi: 10.3389/fbioe.2023.1138596.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Du Y, Liu Y, Hu J, Peng X, Liu Z. CRISPR/Cas9 systems: Delivery technologies and biomedical applications. Asian J Pharm Sci. 2023 Nov;18(6):100854. doi: 10.1016/j.ajps.2023.100854.</mixed-citation><mixed-citation xml:lang="en">Du Y, Liu Y, Hu J, Peng X, Liu Z. CRISPR/Cas9 systems: Delivery technologies and biomedical applications. Asian J Pharm Sci. 2023 Nov;18(6):100854. doi: 10.1016/j.ajps.2023.100854.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, Liu X, Lv Z, Yang P, Xu W, Gao W, Wu Y. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer. 2021 Oct 1;20(1):126. doi: 10.1186/s12943-021-01431-6.</mixed-citation><mixed-citation xml:lang="en">Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, Liu X, Lv Z, Yang P, Xu W, Gao W, Wu Y. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer. 2021 Oct 1;20(1):126. doi: 10.1186/s12943-021-01431-6.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Drago D, Foss-Campbell B, Wonnacott K, Barrett D, Ndu A. Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs. Mol Ther Methods Clin Dev. 2021 Apr 5;21:524-529. doi: 10.1016/j.omtm.2021.04.001.</mixed-citation><mixed-citation xml:lang="en">Drago D, Foss-Campbell B, Wonnacott K, Barrett D, Ndu A. Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs. Mol Ther Methods Clin Dev. 2021 Apr 5;21:524-529. doi: 10.1016/j.omtm.2021.04.001.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Watters KE, Kirkpatrick J, Palmer MJ, Koblentz GD. The CRISPR revolution and its potential impact on global health security. Pathog Glob Health. 2021 Mar;115(2):80-92. doi: 10.1080/20477724.2021.1880202.</mixed-citation><mixed-citation xml:lang="en">Watters KE, Kirkpatrick J, Palmer MJ, Koblentz GD. The CRISPR revolution and its potential impact on global health security. Pathog Glob Health. 2021 Mar;115(2):80-92. doi: 10.1080/20477724.2021.1880202.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Morshedzadeh F, Ghanei M, Lotfi M, Ghasemi M, Ahmadi M, Najari-Hanjani P, Sharif S, Mozaffari-Jovin S, Peymani M, Abbaszadegan MR. An Update on the Application of CRISPR Technology in Clinical Practice. Mol Biotechnol. 2024 Feb;66(2):179-197. doi: 10.1007/s12033-023-00724-z.</mixed-citation><mixed-citation xml:lang="en">Morshedzadeh F, Ghanei M, Lotfi M, Ghasemi M, Ahmadi M, Najari-Hanjani P, Sharif S, Mozaffari-Jovin S, Peymani M, Abbaszadegan MR. An Update on the Application of CRISPR Technology in Clinical Practice. Mol Biotechnol. 2024 Feb;66(2):179-197. doi: 10.1007/s12033-023-00724-z.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
